Corteva : Investor Update with Chief Executive Officer and Chief Financial Officer

Investor Update

James C. Collins, Jr Chief Executive Officer

Greg Friedman EVP & Chief Financial Officer

August 17, 2020

Safe Harbor Regarding Forward-Looking Statements

Forward-Looking Statements

This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, as well as expected benefits from, the separation of Corteva from DuPont, are forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to successfully develop and commercialize Corteva's pipeline; (ii) effect of competition and consolidation in Corteva's industry; (iii) failure to obtain or maintain the necessary regulatory approvals for some Corteva's products; (iv) failure to enforce Corteva's intellectual property rights or defend against intellectual property claims asserted by others; (v) effect of competition from manufacturers of generic products; (vi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (ix) effect of changes in agricultural and related policies of governments and international organizations; (x) effect of industrial espionage and other disruptions to Corteva's supply chain, information technology or network systems; (xi) competitor's establishment of an intermediary platform for distribution of Corteva's products; (xii) effect of volatility in Corteva's input costs; (xiii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xiv) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva, including failure to benefit from significant cost synergies; (xvi) risks related to the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) effect of compliance with environmental laws and requirements and adverse judgments on litigation; (xix) risks related to Corteva's global operations; (xx) effect of climate change and unpredictable seasonal and weather factors; (xxi) effect of counterfeit products; (xxii) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxiii) risks related to non-cash charges from impairment of goodwill or intangibles assets; (xxiv) risks related to COVID-19; (xxv) risks related to oil and commodity markets, and (xxvi) other risks related to Corteva's Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent reports on Forms 10-Q and Current Reports on Form 8-K.

2

A Reminder About Non-GAAP Financial Measures and Pro Forma Financial Information

Corteva Unaudited Pro Forma Financial Information

In order to provide the most meaningful comparison of results of operations, supplemental unaudited pro forma financial information for the first quarter of 2019 has been included in this presentation. This presentation presents the pro forma results of Corteva, after giving effect to events that are (1) directly attributable to the merger of DuPont and Dow, debt retirement transactions related to paying off or retiring portions of Historical DuPont's existing debt liabilities, and the separation and distribution to DowDuPont stockholders of all the outstanding shares of Corteva common stock; (2) factually supportable and (3) with respect to the pro forma statements of income, expected to have a continuing impact on the consolidated results. Refer to Corteva's Form 10 registration statement filed on May 6, 2019, which can be found on the investors section of the Corteva website, for further details on the above transactions. The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X, and are presented for informational purposes only, and do not purport to represent what the results of operations would have been had the above actually occurred on the dates indicated, nor do they purport to project the results of operations for any future period or as of any future date.

Regulation G (Non-GAAP Financial Measures)

This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, pro forma operating EBITDA, operating EBITDA margin, pro forma operating EBITDA margin, operating earnings per share, pro forma operating earnings per share, base tax rate and pro forma base tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results.

These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies For first quarter 2019 and prior, these non-GAAP measures are being reconciled to a pro forma GAAP financial measure prepared and presented in accordance with Article 11 of Regulation S-X. Reconciliations for these non-GAAP measures to their most directly attributable U.S. GAAP measure are provided on slides 21 - 23 of this presentation.

Corteva is not able to reconcile its forward-lookingnon-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as Significant Items, without unreasonable effort. For Significant Items reported in the periods presented, refer to page A-9 of the Financial Statement Schedules. Beginning January 1, 2020, the company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-yearramp-up period of Enlist E3®, Corteva is expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform after the completion of the ramp-up.

Organic sales is defined as price and volume and excludes currency and portfolio impacts. Operating EBITDA is defined as earnings (i.e., income from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits, net and foreign exchange gains (losses), excluding the impact of significant items (including goodwill impairment charges). Non-operating benefits, net consists of non-operating pension and other post-employment benefit (OPEB) credits, tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Operating earnings per share are defined as "Earnings per common share from continuing operations - diluted" excluding the after-tax impact of significant items (including goodwill impairment charges), the after-tax impact of non-operating benefits, net, and the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Base tax rate is defined as the effective tax rate excluding the impacts of foreign exchange gains (losses), non-operating benefits, net, amortization of intangibles as of the Separation from DowDuPont, and significant items (including goodwill impairment charges). All periods for the first quarter of 2019 and prior are on a pro forma basis as discussed above in the paragraph 'Corteva Unaudited Pro Forma Financial Information'.

3

Looking Beyond the Crisis to the Future

1

2

3

4

Operational momentum is clear

Strategy is durable

Growth expectations are achievable

Execution is disciplined and focused

4

Keeping our Priorities for Shareholder Value Creation in Focus

Accomplishments through 1H 2020(1)

• Launched key seed technologies in corn and soybeans
• Delivered seed price improvement in all regions
• Implemented multi-channel,multi-brand strategy
• Delivered insecticide growth
• Implemented best owner strategy in Crop Protection
• Delivered more than $300 million in earnings improvement from new Crop Protection products
• Realized merger cost synergies and productivity of ~$930 million since merger close
• Approved capacity expansion in Spinosyn insecticides
• Acquired PhytoGen Seed Company - cottonseed asset
• Returned approximately $400 million to shareholders since spin through dividends
• Repurchased $75 million in shares

Mid-Term Focus

• Accelerate Enlist E3®(2) soybean launch
• Continue corn technology penetration globally
• Scale Brevant™ seed brand in key markets
• Increase patented and differentiated Crop Protection sales
• Deliver ~$400 million in earnings improvement from new Crop Protection products
• Drive ~$1 billion of additional cost savings and productivity
• Fund key product and pipeline growth
• Pursue opportunistic, bolt-on M&A
• Maintain competitive dividend policy
• Complete the $1 billion share repurchase program
• Optimize pension liability

(1)	Accomplishments represent the time period between the close of the DowDuPont merger and 1H 2020, unless otherwise stated.
(2)	The transgenic soybean event in Enlist E3® soybeans is jointly developed and owned by Dow AgroSciences LLC and M.S. Technologies, L.L.C. Royalty income for Enlist E3® is shared with MS Technologies.	5

Earnings Expansion through Penetration of Enlist E3®(2) Soybean System

Market Opportunity

% of Market

Driving Earnings Improvement with Proprietary System

				~50%
>20%	~30%
	2020E	2021E	Peak
% Acres Treated	2020E	2021E	Peak
with Enlist™	~70%	~65%
Herbicide	~65%

Corteva Opportunity

% of volumes	~90%

~35%

17%

2020E 2021E Peak

% CTVA 2020E 2021E Peak

Germplasm ~10% ~25% 100%

Targeted Annualized Earnings >$400 million1

Improvement at Peak

Components of Earnings Improvement

• Reduction of royalty costs for in-licensed traits and germplasm
• Royalty income on out-licensing of trait(2)
• Herbicide margins for Corteva branded acres

•	Market share expansion opportunity	Incremental upside
excludedfrom
•	Value capture on best-in-class performance	~$400 million in
annualized improvement

1. Annualized improvement reflects earnings improvements from reduced in-licensed trait and germplasm costs, out-licensing income for Enlist E3® trait and benefit from Enlist™ herbicide. Estimate does not include any

assumption for changes in market share or pricing opportunity for Enlist E3® seed.	6
(2) The transgenic soybean event in Enlist E3® soybeans is jointly developed and owned by Dow AgroSciences LLC and M.S. Technologies, L.L.C. Royalty income for Enlist E3® is shared with MS Technologies.

Driving Corn Seed Price Improvement with New Technology

Qrome® Sales

Extracting Value on Yield-Advantaged Technology

$ billions

~ $0.7

~ $1.1

~ $0.8

2019 Yield Advantage(1)

8.2 bu/A1

	2020 Pricing	>$40
6.9 bu/A2	Improvement
	- North	million
	America

2020E 2021E Peak

Branded Offering

% of volumes

		Corn(2)
Corn on corn	All
	acres/rotations

Superior performance on best-in-class genetics

~20%

> 35%

~25%

• Proprietary molecular-stack technology with proven insect protection and dual modes of action defend against above- and below-ground pests

• Maximum corn rootworm control - balancing insect protection and agronomics for industry-leading performance

2020E 2021E Peak

Triple-stack market represents approximately 1/3 of total North America corn acres

• Compatible with a wide range of Corteva germplasm

(1)	2019 comparison data is based on the average of 1,330+ comparisons1 and on the average of 3,500+ comparisons2 made in the U.S. through Nov. 1, 2019. Comparisons are against all competitors, technology segment matched,
	unless otherwise stated, and within +/- 3 CRM of the competitive brand. Product responses are variable and subject to any number of environmental, disease and pest pressures. Individual results may vary. Multi-year and multi-	7
	location data are a better predictor of future performance.
(2)	Based on 2020 season.

Multi-Brand,Multi-Channel Approach Expands Market Presence

Multiple Seed Brands

Four Differentiated Channels

Premium

Global

Seed

Brands

Regional

Pioneer Agency Model

Exclusive to Pioneer seed brand - direct to farmer via independent Pioneer sales representatives

Regional Seed Brands

Connects customers to our regional brand employees or farmer-dealer networks

and Retail Po

Seed

Brands

Retail

Some seed brands - including Brevant™ Seeds - via wholesale, independent and distribution-owned retailers

Licensing and Distribution

Strategic distribution and licensing opportunities with retailers and independent seed companies outside our brands

Unique customer value proposition defined by differentiated product and service offerings delivered through each brand

Recently announced introduction of Brevant™ seed brand in the U.S. for sale exclusively through retail, focused in the Midwest and Eastern

Corn Belt starting in 2021 season

Executing Strategy to Enhance Market Presence in the Retail Channel

8

Scaling Brevant™ Seed Brand in Key Global Retail Markets

• With an initial launch in 2018, Brevant™ seed brand has now launched in 11 countries to date, including the U.S., Canada, Brazil and Argentina
• As a global brand, Brevant™ provides farmers greater choice with a high-performance retail solution
• Brand has received favorable customer response and is a sales and earnings growth driver for the Seed segment in the mid-term
• Greater than 6 million units sold globally

North America

Recently announced introduction of Brevant™ seed brand in the U.S.

for sale exclusively

Po

through retail, focused in the Midwest and Eastern Corn Belt starting in 2021 season

Latin America

Launched Brevant™

seed brand in Brazil in 2018 and increased sales by 15%Po since that date - expanded market share by more than 100 basis points in Brazil corn market

Launched in Key Countries Globally to Drive Penetration in the Retail Channel

9

Shaping the Crop Protection Portfolio of the Future

Portfolio

Rationalization

Completed 4 portfolio divestitures since separation, and exited Chlorpyrifos - reinforcing commitment to active portfolio management focused on margin expansion and value creation

Cross

Licensing

Strategic partnerships strengthen portfolio co-development and research funding & risk share - >70 agreements announced since separation

Organic

Growth(1)

Ramping up new product sales and driving sales of differentiated higher margin technology while continuing to invest in R&D and advancing pipeline

Acquisitions

Recently announced multi-year global agreement reflecting continued commitment to growing biologicals portfolio, while increasing technology differentiation and competitive advantage

2019 CP Sales	2020E CP Sales(2)	2023E CP Sales Vision(2)
Patented	Patented	Off-Patent	Patented
19%	22%
50%	34%

Off-Patent	Differentiated	Off-Patent	Differentiated
12%	14%	Differentiated
69%	64%
		16%

Driving a best-owner strategy and disciplined portfolio management focus

Source: Internal analysis.	10
(1)	Organic sales growth is defined as price and volume, excluding currency and portfolio impact.
(2)	Estimated.

New Crop Protection Products Drive Sales and Margin Diversity

New Crop Protection

Product Sales

	Net Sales			160%
	$ millions
	~$2,600
		~$1,000
		$750
	$450

2018

2019

2020E

2023E

New Insecticide Product Sales

$200 MM	>$300 MM		$80 MM	>$150 MM
>50%	>90%		Est. 2021 Launch	(1)
2020E	2023E	2020E	2023E

New Herbicide Product Sales

$200 MM	>$600 MM	>200%	$90 MM	>$200 MM	>120%	$150 MM	>$300 MM	>100%
2020E	2023E	2020E	2023E	2020E	2023E

New Fungicide Product Sales

$150 MM	>$200 MM		$10 MM	>$275 MM		$100 MM	>$200 MM
>33%	>27x	Est. 2023 Launch(1)	>100%
2020E	2023E		2020E	2023E			2020E	2023E

New Active Ingredients and Formulations Drive Incremental Sales and Margins

(1) Estimated launches pending all applicable regulatory approvals.

11

Expanding Position in Growing Insecticide Market

Market Opportunity

$ in billions

$14.5

$13.9

$13.3

2018 2019 2020E

Corteva Sales

$ in billions

$1.51 $1.65 $1.76 $2.03

2018 2019 2020E 2023E

Currency Impact

$ in millions
Currency ~$(25) MM	~$(65) MM	~$(120) MM
2018	2019	2020E

• Novel, technology with fast- acting and long-lasting control for hard-to-control insect pests - targeted for use in fruits and vegetables, cereals, soybeans and rice
• U.S. EPA restored registration in 2020 - expanded critical uses

$200 MM	>$300 MM	>50%
2020E New	2023E New
Product Sales	Product Sales

• Novel, insect control solution targeted for Asian rice growers
• Differentiated MOA and no cross resistance

$80 MM	>$150 MM	>90%
2020E New	2023E New
Product Sales	Product Sales

Spinosyns Insecticides

Spinosad Spinetoram

• Naturally derived insecticide developed and manufactured through proprietary process
• Provides organic farmers with highly effective and needed insect control option with broad spectrum offering for insect control in key crops such as fruits, vegetables, soybean and others
• Unique, world-class fermentation facilities and processes enable us to innovate natural products and increase productivity and scalability
• Authorized Spinosyns capacity expansions are expected to deliver 50% increase in fermentation capacity by 2023

$770 MM	>$1 B
2020E	2023E	>30%
Differentiated	Differentiated
Product Sales	Product Sales

12

New Products Enabling Differentiation and Growth in Herbicides

Market Opportunity

• Novel, with new MOA for

fast, effective control of hard-

• Enlist One® offers additional

$ in billions

$27.7 $28.0

$28.9

to-control broadleaf weeds

for the cereals, OSR and

sunflower markets

• Innovative resistance

management tool with low

use rates

tank-mix flexibility and provides exceptional weed control designed to land and stay on target

• Enlist Duo® provides two sites of action that work together to deliver control and help prevent resistance.

2018 2019 2020E

Corteva Sales

$ in billions

			>$3.89
$3.42	$3.27	$3.19				New
						Products
						Base
						Business
2018	2019	2020E	2023E

Currency Impact

$ in millions

Currency ~$(40) MM ~$(100) MM ~$(160) MM

2018 2019 2020E

$200 MM	>$600 MM	>200%
2020E New	2023E New
Product Sales	Product Sales

• Novel, effective broad spectrum post-emergenceweed-control solution for rice markets, with new MOA
• Targeted site resistance with low use rates
• Recipient of multiple "green chemistry" awards

$90 MM	>$200 MM	>120%
2020E New	2023E New
Product Sales	Product Sales

$150 MM	>$300 MM	>100%
2020E New	2023E New
Product Sales	Product Sales

• Accelerated production of
  Enlist™ herbicides, ahead of the
  2021 selling season
• Ramp-upplan focuses on the solid long-term fundamentals of
  Enlist™ weed control system

13

Targeted Actions to Build Strength in Fungicides

Market Opportunity

$ in billions

$17.4

$17.0 $17.1

2018 2019 2020E

Corteva Sales

• Novel fungicide for the

management of key diseases

in soybean, corn, wheat, rice, sunflower, canola and OSR

• Onmira™ Active reflects
  Corteva superior research, development and testing

$150 MM	>$200 MM	>33%
2020E New	2023E New
Product Sales	Product Sales

• Novel, naturally derived fungicide for the management of key diseases in cereals and banana
• Favorable regulatory profile

$10 MM	>$275 MM	>27x
2020E New	2023E New
Product Sales	Product Sales

$ in billions

$1.14 $1.08 $1.06

$1.38

Emerging Fungicides Portfolio

•Expanding market presence in line with rapid ramp-up of new products

• New site and MOA fungicide

for the management of key

diseases in potatoes, grapes

and vegetables

2018 2019 2020E 2023E

Currency Impact

$ in millions
Currency ~$(65) MM	~$(45) MM	~$(130) MM
2018	2019	2020E

•Product development rigor, coupled with favorable regulatory profiles on technologies, expected to accelerate competitive advantages

• Favorable regulatory profile

$100 MM	>$200 MM
2020E New	2023E New	>100%
Product Sales	Product Sales

14

Focused Emphasis on Productivity and Removing Inefficiencies

~$930 million realized to date, ~$1.0 billion additional savings expected to be realized

Merger-Related Synergies

Continued realization of $1.2 billion merger-related synergies through 2021

~$900 million realized through 2Q 2020

Remaining programs focus on COGS improvements via operational footprint and procurement

ERP Harmonization

~$200 million in "dis-synergies" as a result of disparate ERP systems

~$300 million investment with approximately 50% of the costs capitalized

Expect to begin achieving savings in 2023

Productivity Program

Instilling "owner mindset" across the organization to drive accretive return

Executing on ~$30 million in savings targeted for 2020

$500 million savings run-rate by 2024

2020 Spending Actions

Announced ~$100 million in spending actions to increase cash and financial resiliency

Expect to maintain the majority of savings run- rate based on new operating environment for foreseeable future

Global Team Engaged in Driving and Sustaining Productivity Benefits

15

Application of Digital Tools to Create Operating Leverage

InternalExternal

	Pipeline	Enterprise	Customer
	Innovation	Software
		Delivering Continued Progress on Digital Transformation Strategy
› Automation, data science and digital	› Enterprise strategy & applications	› SaaS(1) through Granular
	tools in R&D	›Process automation	Customer experience
	Reduced costs	›Data-drivendecision-making	Farmer profitability

Accuracy	Improved customer experience	Standalone revenue
Speed of new product introduction	Cross-selling opportunities	Cross-selling opportunities
	Reduced costs

2020 Achievements Against Backdrop of COVID-19

• Providing agronomic services remotely - currently conducting drone flights to help U.S. growers do seed counts and scouting via Corteva Flight program

• First ERP Module delivered
• Secured first electronic Crop Protection registrations

• Expanding the use of digital marketing tools to facilitate customer training and product knowledge transfer

Extracting Additional Benefit from Investments in Digital Tools

1. "Software as a service"

16

Prioritizing Capital Deployment Actions to Drive Stronger Returns

	Healthy Balance Sheet		Growth Investment		Return Cash to Shareholders
	Committed to Maintain		Strategic Investments		Opportunistic M&A		Competitive Dividend		Share Repurchase
	an A- Credit Profile(1)				Policy
	› Maintain		› Investing in		› Opportunistic to		› Targeting 25-	› Committed to
	financial		innovation for		accelerate		35% of net	return excess
	flexibility to		customers		competitive		income with	cash to
	support industry		including R&D		advantage and		earnings and	shareholders
	leading		investment and		expand reach in		free cash flow
	business model		capital		key strategic		growth(2)
			expenditures		sectors and
					adjacencies

(1)	Target rating (expressed using S&P nomenclature).
(2) Corteva's dividend policy and associated actions are subject to the approval of the Corteva Board of Directors.	17

Appendix

Differentiated Crop Protection Products Enable Competitive Advantages

Differentiated Crop

Protection Product Sales

Net Sales

$ millions	35%

Spinosyns Insecticides

Spinosad Spinetoram

•	Naturally derived insecticide developed and
	manufactured through proprietary process
•	Provides organic farmers with highly
	effective and needed insect control option

$680 $760

>$1,160

$860

$770 MM	>$1 B	>30%
2020E	2023E

Optinyte™ Technology

with broad spectrum offering for insect

control in key crops such as fruits,

vegetables, soybean and others

• Enables Nitrogen to remain available in the

root zone longer for crop uptake

• Supports increases in yield in corn (maize),

2018

2019

2020E

2023E

$90 MM	>$160 MM	>80%
2020E	2023E

cereals, and many other crops

• Improves crop quality and plant health

Creating Value for Customers and Driving Returns via Proprietary Technology

19

Product Disclosures

TM ® SM Trademarks and service marks of Dow AgroSciences, DuPont or Pioneer, and their affiliated companies or their respective owners. © 2020 Corteva

The transgenic soybean event in Enlist E3TM soybeans is jointly developed and owned by Dow AgroSciences LLC and M.S. Technologies, L.L.C. The Enlist weed control system is owned and developed by Dow AgroSciences LLC. Enlist Duo® and Enlist One® herbicides are not registered for sale or use in all states or counties. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your area. Enlist Duo and Enlist One are the only 2,4-D products authorized for use with Enlist crops. Consult Enlist herbicide labels for weed species controlled. Always read and follow label directions.

Qrome® products are approved for cultivation in the U.S. and Canada. They have also received approval in a number of importing countries, most recently China. For additional information about the status of regulatory authorizations, visit http://www.biotradestatus.com/

Pioneer® brand products are provided subject to the terms and conditions of purchase which are part of the labeling and purchase document.

20

Corteva

Non-GAAP Calculation of Corteva Operating EBITDA

			Six Months Ended June 30,
			2020		2019
	In millions		As Reported		Pro Forma
	Income from continuing operations, net of tax (GAAP)	$	1,047	$	595
	Provision for income taxes on continuing operations		205		250
	Income from continuing operations before income taxes	$	1,252	$	845
	+ Depreciation and Amortization		583		485
	- Interest income		(27)		(33)
	+ Interest expense		24		48
	+ / - Exchange (gains) losses, net		60		59
	+ / - Non-operating benefits, net		(164)		(74)
	+ Significant items charge		302		640
	Corteva Operating EBITDA (Non-GAAP)1	$	2,030	$	1,970

1. Corteva Operating EBITDA is defined as earnings (i.e., income from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs) - net and foreign exchange gains (losses), excluding the impact of significant items. Non-operating benefits (costs) - net consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, environmental remediation and legal costs associated with Historical DuPont businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

21

Corteva

Segment Information - Price, Volume Currency Analysis

Region

			Six Months Ended June 30, 2020 vs. Six Months Ended June 30, 2019			Percent Change Due To:
			Net Sales Change (GAAP)			Organic Change (Non-GAAP)2		Local Price &
		$	(millions)		%		$	(millions)		%		Product Mix	Volume	Currency	Portfolio / Other
	North America1	$		154		3%	$		179		3%	0%	3%	0%	0%
	EMEA1			79		4%			173		8%	2%	6%	-4%	0%
	Latin America			(69)		-7%			66		7%	7%	0%	-14%	0%
	Asia Pacific			31		4%			75		10%	2%	8%	-5%	-1%
	Rest of World			41		1%			314		8%	3%	5%	-7%	0%
	Total	$		195		2%	$		493		5%	1%	4%	-3%	0%

Seed

			Six Months Ended June 30, 2020 vs. Six Months Ended June 30, 2019			Percent Change Due To:
			Net Sales Change (GAAP)			Organic Change (Non-GAAP)2		Local Price &
		$	(millions)		%		$	(millions)		%		Product Mix	Volume	Currency	Portfolio / Other
	North America1	$		181		5%	$		190		5%	1%	4%	0%	0%
	EMEA1			67		6%			119		11%	4%	7%	-5%	0%
	Latin America			57		16%			105		29%	9%	20%	-13%	0%
	Asia Pacific			22		10%			36		17%	8%	9%	-7%	0%
	Rest of World			146		9%			260		16%	6%	10%	-7%	0%
	Total	$		327		6%	$		450		8%	2%	6%	-2%	0%

Crop Protection

		Six Months Ended June 30, 2020 vs. Six Months Ended June 30, 2019			Percent Change Due To:
		Net Sales Change (GAAP)		Organic Change (Non-GAAP)2		Local Price &
		$ (millions)		%		$ (millions)		%		Product Mix	Volume	Currency	Portfolio / Other
	North America1	$	(27)		-2%	$	(11)		-1%	-1%	0%	0%	-1%
	EMEA1		12		1%		54		6%	1%	5%	-4%	-1%
	Latin America		(126)		-19%		(39)		-6%	5%	-11%	-13%	0%
	Asia Pacific		9		2%		39		8%	0%	8%	-4%	-2%
	Rest of World		(105)		-5%		54		3%	2%	1%	-7%	-1%
	Total	$	(132)		-4%	$	43		1%	1%	0%	-4%	-1%

1. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa.

2. Organic sales is defined as price and volume and excludes currency and portfolio impacts.

22

Corteva

Non-GAAP Calculation of Adjusted Return on Invested Capital (ROIC)

Adjusted Invested Capital (in millions)

		March 31, 2019			June 30, 2019		S eptember 30, 2019		December 31, 2019		Trailing Twelve Months
		Pro Forma			As Reported		As Reported		As Reported		Pro Forma
	Goodwill	$	10,203	$	10,249	$	10,168	$	10,229	$	10,212
	Other intangible assets		11,961		11,832		11,667		11,424		11,721
	Total goodwill and other intangible assets (existing as of S eparation)		22,164		22,081		21,835		21,653		21,933
	Short term borrowings and finance lease obligations	$	2,716	$	2,058	$	3,604	$	7	$	2,096
	Long-term debt		183		117		116		115		133
	Total Debt		2,899		2,175		3,720		122		2,229
	Total Equity 1		25,145		26,067		25,261		24,555		25,257
	Total Debt plus Equity		28,044		28,242		28,981		24,677		27,486
	Total Debt plus Equity, less goodwill and other intangible assets
	(existing as of S eparation) ("Adjusted Invested Capital")	$	5,880	$	6,161	$	7,146	$	3,024	$	5,553
	Adjusted NOPAT 2	$	1,099
	Adjusted Invested Capital	$	5,553
	Adjusted Return on Invested Capital 3		19.8%

1.	T he company has revised the balance of additional paid in capital as of 6/30/2019 in the amount of $76 million to reflect the removal of an asset related to the Separation.
2.	Adjusted NOPAT is defined as net income from continuing operations attributable to Corteva excluding the after-tax impact of significant items (including goodwill impairment charges), the after-tax impact of non-operating benefits, net, the after-tax impact of

amortization expense associated with intangible assets existing as of Separation, the after-tax impact of interest income and the after-tax impact of interest expense divided by debt plus equity excluding goodwill and intangibles (existing as of Separation). 3. Adjusted Return on Invested Capital ("ROIC") is defined as Adjusted NOPAT divided by debt plus equity excluding goodwill and intangibles (existing as of Separation).

23